Background: Elevated JAK2V617F allele
burden is associated with enhanced expression of
downstream target genes in Philadelphia negative
chronic myeloproliferative neoplasms (CMPNs) which
include PV, ET & PMF. Previous studies have
shown the impact of JAK2V617F allele burden on
clinical phenotype of CMPNs. However, there is no
data from India regarding the association between
JAK2V617F allele burden and clinical phenotype in
PV. Aims/Settings and Design: We aimed to
investigate the effect of allele burden on
clinical phenotype in 90 JAK2V617F positive PV
patients and to see its influence on disease
related complications. Material and Methods:
Allele burden of 90 JAK2V617F positive PV patients
was quantified by Real-time polymerase chain
reaction (RQ-PCR). Results: 74/90 (82.22%) were
males and 16/90 (17.78%) were females (median 45
years, range 35-78). Patients with age >50
years had significantly higher JAK2V617F allele
burden (median 40.15%, range 0.49–91.62 %) than
patients with ≤ 50 years age (median 48.59 %,
range 0.56–86.74 %; P < 0.032). Patients with
splenomegaly had significantly higher JAK2V617F
allele burden (mean 50.24%, range 6.91–84.17%)
than patients without splenomegaly (mean 33.82 %,
range 0.49–71.83 %; P < 0.017). Patients with
higher allele burden (median 57.20, range
43.4–72.03%) had significantly raised thrombotic
events than the patients with lower allele burden
(median 37.38, range 0.49–84.17% P < 0.043).
49/90 (54%) were homozygous and 41/90 (46%) were
heterozygous. Conclusions: Higher JAK2V617F allele
burden showed association with increased age,
splenomegaly and thrombotic events. Thus, it may
be considered for prognostication and setting up
the treatment protocol in PV patients.
Our study suggests that JAK2V617F mutation may increase the risk of thrombosis in CMPNs. This finding could lead to risk stratification, setting up the treatment strategy in CMPNs.
Chronic Myelogenous Leukemia (CML) is a myeloproliferative neoplasm characterized by proliferation of Philadelphia positive clonal pluripotent hematopoietic cells. Bleeding is a rare presentation of CML that can occur due to platelet dysfunction. Both pre-treatment and post-treatment platelet function abnormalities in CML have been described in the literature. We describe a rare case of childhood CML who presented with mucocutateous bleeding manifestations. On laboratory workup, a Glanzmann Thrombasthenia (GT) like platelet phenotype was demonstrated along with confirmation of diagnosis of CML in chronic phase. The acquired nature of platelet function defect was confirmed by demonstrating recovery of platelet antigens glycoprotein IIb/IIIa after achieving complete hematological response with Imatinib. Due to presenting complaint of bleeding diathesis and absence of hepatosplenomegaly, the case was undiagnosed for CML until the patient reported to us. Careful evaluation of complete blood counts, peripheral blood picture and detailed laboratory workup was the window to proper diagnosis and treatment in this case.
This study for the first time showed that the mathylation of SOCS-1 gene plays an important role in the disease progression and is associated with poor survival especially among the high-risk patients. This may be due to high association between SOCS1 methylation and higher risk subtypes of MDS (such as RAEB) in this study.
Introduction:The ultimate goal for CML management is risk stratification of the patients to design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were established to prognosticate the patients on therapy.Aim:To perform a comparative assessment of the Sokal, Euro and EUTOS prognostic score in Indian CML-CP patients on imatinib.Methods:This is a retrospective study performed in 260 Ph+ CML-CP patients who were administered oral imatinib (400 mg/day).Results:166/260 were males and 94/260 were females (M: F::1.6:1) with median age 35 years (range 20-70). 92 (35.38%), 125 (48.07%) and 43 (16.5%) patients were divided into low, intermediate and high risk Sokal score respectively. 102 (39.23%), 106 (40.76%) and 52 (20%) patients were discriminated into low, intermediate and high risk Euro score respectively. 210 (80.7%) and 50 (19.2%) patients were divided into low and high risk EUTOS score. Cumulative incidence of MMR for low, intermediate and high-risk Sokal score was 87%, 76% and 84% respectively (P = 0.016). Incidence of MMR in low, intermediate and high-risk Euro score was 93%, 85% and 68% respectively (P = 0.001). Incidence of MMR was 80 % and 81% for low and high risk EUTOS score (P = 0.764). Both EFS and OS are significantly correlated with Sokal score (P = 0.004, P = 0.007) and Euro score (P = 0.009, P = 0.001) but not with EUTOS score (P = 0.581, P = 0.927).Conclusion:The present study highlights the significant prognostic role of Sokal and Euro score in predicting the treatment outcome of the CML- CP patients on imatinib.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.